Compare Transocean Ltd (RIG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs GeneDx Holdings Corp — how do they compare? Transocean Ltd trades at $5.57 (market cap $6.19B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Transocean Ltd is far larger — about 3.1× GeneDx Holdings Corp's market cap, and Transocean Ltd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Transocean Ltd for 18 Days and GeneDx Holdings Corp for 19 Days on average.
| RIG | WGS | |
|---|---|---|
Market Cap | $6.19B | $2.02B |
Volume | 30,564,415 | 734,640 |
Sector | Energy | Health |
52-Week High | $7.58 | $167.51 |
52-Week Low | $3.08 | $34.51 |
Typical Hold Time | 18 Days | 19 Days |
Enterprise Value | $10.80B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.39, down slightly by 0.19%, with a bearish technical signal from moving averages. The company reported a net loss of $2.92 billion in 2025, though revenue remains stable near $4 billion. Recent news highlights the $5.8 billion Valaris acquisition, approved by the DOJ, and new contracts like the $80 million deal for the Deepwater Conqueror, providing operational momentum amid a challenging profitability landscape.
The outlook is speculative, hinging on successful deleveraging and integration of the Valaris deal to improve cash flow. Key risks include high debt levels, execution challenges, and persistent negative margins. Analyst sentiment is mixed, with a 39% buy rating, reflecting cautious optimism tied to offshore cycle strength and debt reduction progress.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
